The pharmaceutical industry is facing a period of significant transformation. Rising research and development costs, increasingly complex regulatory requirements, lengthy development timelines, and the growing impact of the patent cliff (when a drug's patent expires and lower-cost generic versions enter the market) are placing greater pressure on pharmaceutical companies to maximise the value of their existing portfolios [1]. While the drug discovery and development process remains essential for bringing innovative therapies to market, many organisations are also looking beyond new molecules to strengthen long-term growth.
As a result, pharmaceutical lifecycle management has become a strategic priority, with greater focus on enhancing established medicines through drug reformulation, drug repurposing, and drug repositioning [2]. Rather than replacing innovation, these approaches enable companies to improve patient value, extend product relevance, and unlock new commercial opportunities. In today's competitive market, reformulating proven medicines is increasingly recognised as both a scientific advancement and a strategic business decision.
Drug reformulation involves improving an existing medicine without changing its active pharmaceutical ingredient (API). Instead of discovering a completely new molecule, pharmaceutical companies optimise how a medicine is formulated or delivered to address patient needs, improve treatment outcomes, and create additional commercial value. As an incrementally modified drug, a reformulated product can strengthen pharmaceutical lifecycle management while building on the safety and efficacy profile of an established medicine [3].
| Reformulation Strategy | Purpose |
|---|---|
| Orodispersible Tablets (ODTs) | Improve ease of administration, particularly for patients with swallowing difficulties [4]. |
| Modified-release dosage forms | Extend drug release and reduce dosing frequency [5]. |
| Taste masking | Enhance palatability and improve patient acceptance [6]. |
| New dosage strengths | Offer greater dosing flexibility for different patient needs. |
| Fixed-dose combinations | Simplify treatment by combining multiple APIs into one dosage form [7]. |
| Paediatric & geriatric formulations | Address the specific needs of children and older adults [8]. |
Instead of relying only on new medicines, reformulation helps companies maximise the value of existing products by[3]:
Many medicines contain the same active pharmaceutical ingredient (API), making differentiation increasingly important [3].
Drug reformulation can help companies:
Small formulation improvements can make a significant difference to the patient experience. Examples include [9]:
Drug reformulation creates value for both patients and pharmaceutical companies by improving existing medicines while supporting long-term commercial growth.
Bringing a reformulated medicine to market requires more than a good idea. It also depends on the right expertise, manufacturing capabilities, and regulatory knowledge. As a result, many pharmaceutical companies choose to collaborate with experienced partners rather than managing every stage of development in-house [10].
Strategic partnerships help pharmaceutical companies to:
By working with formulation specialists, CDMOs, and licensing partners, pharmaceutical companies can bring reformulated medicines to market more efficiently while focusing on their core business strengths. These collaborations also support portfolio expansion and help unlock new commercial opportunities.
As drug reformulation becomes a more important part of pharmaceutical lifecycle management, the value of experienced development and licensing partners continues to grow. Companies with expertise in formulation development, regulatory pathways, manufacturing, and commercialisation can help pharmaceutical organisations bring reformulated medicines to market more efficiently while managing development risks. This collaborative approach is reflected across the industry, including at Novumgen, where formulation innovation and strategic partnerships support the development and licensing of patient-focused pharmaceutical products. The emphasis remains on helping partners maximise the potential of existing medicines while meeting evolving market and patient needs.
As the pharmaceutical industry continues to evolve, companies are looking for smarter ways to deliver greater value from existing medicines. Drug reformulation offers an opportunity to address changing patient needs while supporting sustainable portfolio growth and long-term innovation. When combined with the right expertise and collaborative partnerships, it can help transform established products into solutions that remain relevant in an increasingly competitive market.
Looking ahead, drug reformulation is expected to play an even greater role in shaping the future of pharmaceutical development - helping organisations balance innovation, efficiency, and patient-centred care.